The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

BACKGROUND: Dupilumab significantly improves symptom control in chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with large polyps at the initiation of treatment (total polyp score (TPS) ≥ 5) have been the focus in published studies. Patients with significant burden of disease but small p...

Descripción completa

Detalles Bibliográficos
Autores principales: Campion, Nicholas J., Brugger, Jonas, Tu, Aldine, Stanek, Victoria, Brkic, Faris F., Bartosik, Tina J., Liu, David T., Hoehl, Bruna S., Gangl, Katharina, Eckl-Dorna, Julia, Schneider, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481502/
https://www.ncbi.nlm.nih.gov/pubmed/37674253
http://dx.doi.org/10.1186/s40463-023-00663-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481502/
https://www.ncbi.nlm.nih.gov/pubmed/37674253
http://dx.doi.org/10.1186/s40463-023-00663-4

Ejemplares similares